Niche Pharmaceutical Valuation Software Business with Low Down Payment

This listing presents a unique opportunity to acquire a niche software business specializing in pharmaceutical valuation. The company's flagship product offers advanced tools for project evaluation and portfolio analysis, providing flexibility and user-friendliness superior to traditional methods like Excel. Its capabilities include real-time decision-making, financial projections, and portfolio optimization using sophisticated modeling techniques such as Monte Carlo simulations and tornado charts. The software is highly customizable and integrates diverse project types, making it attractive to pharmaceutical companies and consulting firms. While revenue has historically been driven by consulting services and licensing fees up to $50,000 annually, the direct software sales model is currently underutilized, presenting significant scaling potential. The sale includes the source code, with the current owner offering paid programming and development support for ongoing evolution. The business requires a low upfront investment of $25,000, with the remaining balance paid via a 20% royalty on future sales, creating a low-risk entry for buyers. The seller will retain usage rights exclusively for consulting, allowing the buyer full control over software sales expansion. A smooth transition is assured with seller support, training, and the willingness of experienced staff to continue with the new owner. The business was established in 2020 and is located in Las Vegas, Nevada.